Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19733424 | 0.80 | TNK2 (0.49) | BTKTNK2SRCTLR7ABL1 | |
| SCHEMBL463424 | 0.79 | BTK (0.50) | BTKIGF1RTNK2SRCABL1 | |
| SCHEMBL21733204 | 0.79 | BTK (0.32) | BTKSRC | |
| SCHEMBL12165128 | 0.76 | BTK (0.51) | BTKIGF1RTNK2SRCABL1 | |
| SCHEMBL23044547 | 0.76 | BTK (0.48) | BTKIGF1RTNK2SRCABL1 | |
| SCHEMBL16900158 | 0.76 | ALDH1A1 (0.33) | BTKIGF1R | |
| SCHEMBL13201547 | 0.76 | BTK (0.48) | BTKIGF1RTNK2SRCABL1 | |
| SCHEMBL24696960 | 0.75 | BTK (0.47) | BTKIGF1RTNK2SRCTLR7 | |
| SCHEMBL23508975 | 0.75 | BTK (0.35) | BTKIGF1R | |
| SCHEMBL6938371 | 0.73 | TNK2 (0.52) | BTKTNK2SRCTLR7ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332057-A1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332057-A1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | BTK, LCK, SYK | BTK 1/4885IGF1R 1986/4885TNK2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.